54results about How to "Block binding" patented technology

The invention relates to a neutralizing antibody for resisting a novel coronavirus SARS-Cov-2 and an application of the neutralizing antibody. The antibody at least comprises one of a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3. The antibody can be used for preparing a diagnostic reagent or a diagnostic kit, a drug or a pharmaceutical composition for detecting, preventing and treating a COVID-19. According to the neutralizing antibody, differential antibody screening is carried out through a phage display technology ina manner of targeting SARS-Cov-2-RBD and SARS-Cov-1-RBD; the neutralizing antibody for resisting the novel coronavirus SARS-Cov-2 is obtained; binding of the SARS-Cov-2-RBD and ACE2 positive cells can be blocked; and the neutralizing antibody has a remarkable virus neutralizing effect on an SARS-Cov-2 pseudo virus and provides an effective alternative antibody drug for prevention and treatment ofthe COVID-19.

The invention relates to an anti-mouse TIGIT (T cell Ig and ITIM domain), and a hybridoma cell strain mTIGIT-mAb-13G6 (the preservation NO: CCTCC NO: C201299) for producing the monoclonal antibody, and further relates to a preparation method and the application of the monoclonal antibody. The monoclonal antibody can efficiently prevent combination of mTIGIT and mPVR (poliovirus receptor), and can be used for Western blot, ELISA and Flow Cytometry for mTIGIT molecule detection.

The invention provides a polypeptide capable of inhibiting novel coronavirus, belonging to the field of biological medicines. The polypeptide is 2019-nCov-P1 or 2019-nCov-P2 which respectively have anamino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2. The polypeptide can be specifically combined with an S protein HR2 region of COVID-19, so the combination of viruses and cells is blocked, and the virus infection is effectively inhibited and controlled. The invention also provides an application of the polypeptide in preparation of a medicine for preventing and / or treating COVID-19.

The present invention provides an antibody or an antigen-binding fragment thereof that binds to NGF, and lists amino acid sequences of the heavy and light chain variable regions of the antibody. The NGF antibody or the antigen-binding fragment thereof provided by the invention has high affinity for NGF, and can effectively block the binding between the NGF receptor and NGF. The antibody or the antigen-binding fragment thereof inhibits the binding activity of NGF and the receptor in vitro, and is suitable for treating pain diseases associated with expression hyperfunction and elevated levels ofNGF.

The present invention provides a CSF-1R reporter gene cell line and a construction method and an application thereof. The reporter cell line comprises NF-kappa-B reporter gene plasmids; the NF-kappa-Breporter gene plasmids comprise a luciferase reporter gene; and the reporter gene cell line also comprises CSF-1R expression plasmids. The reporter gene cell line expresses human-derived CSF-1R on cell membrane and intracellularly expresses luciferase in response to NF-kappa-B signals, CSF-1 / IL-34 can specifically activate the expression of the luciferase of the reporter gene cell line in a dose-dependent manner, at the same time target antibody drugs of the CSF-1R to block the CSF-1 / IL-34 and bind the CSF-1R on surfaces of the reporter gene cell line, and have important applications in detection of antibody drug activity.

The invention provides a novel CD47 antibody or an immunocompetence fragment thereof, or a composition including the antibody / immunocompetence fragment. The CD47 antibody cannot cause red cell agglutination, and shows low combination at an extremely weak level or non-combination with red cells and blood platelets. The invention provides nucleic acid coding the CD47 antibody or the immunocompetencefragment, an expression vector and a host cell. In addition, the invention provides the purpose of the CD47 antibody or a medical composition containing the CD47 antibody / immunocompetence fragment for preparation of medicines for treating CD47 mediated diseases.

The invention provides an antibody or a fragment thereof aiming at PD-L1, a coding nucleic acid of the antibody or the fragment thereof, a composition containing the antibody or the fragment thereof and the like, and application of the antibody or the fragment thereof to treatment of diseases. The antibody or the fragment thereof can specifically bind to human PD-L1 and block the binding of PD-L1 and PD-1, has a strong ADCC effect on target cells, and can significantly inhibit tumor growth.

The invention provides a single variable domain antibody targeting human programmed death ligand 1 (PD-L1) and a derivative of the single variable domain antibody. PBMC (peripheral blood mononuclear cell) is extracted from a human PD-L1 immunized camel to construct a phage surface display VHH antibody library, an anti-human PD-L1 specific single variable domain antibody 2-2F2 is obtained through screening and identification, and a chimeric antibody chF2 and a humanized modified antibody hzF2 mutant are prepared on the basis of the anti-human PD-L1 specific single variable domain antibody 2-2F2. The affinity of the hzF2 mutant can reach or even exceed that of an initial single variable domain antibody 2-2F2, binding of PD-1 and PD-L1 can be blocked in vitro, and growth of tumors can be inhibited in a tumor-bearing mouse in-vivo test.

The invention provides an antibody binding to programmed cell death protein 1 (PD-1), or a fragment of the antibody, and an application of the antibody or the fragment of the antibody to preventing ortreating of tumors or cancers. The antibody or the fragment of the antibody can effectively block interaction of PD-1 / PD-L1 and PD-1 / PD-L2, has a unique antigen binding epitope, and has unique properties in drug effect and safety.

The invention belongs to the technical field of agricultural product processing devices, relates to a pulverizing device, and in particular relates to a yacon fruit flake and whole powder multielementjoint processing production system. A pretreatment unit, a peeling and slicing unit, an anti-browning unit, an anti-caking treatment unit and a high-speed nitrogen flow pulverizing unit are mounted sequentially from the upstream side to the downstream side of the working procedure, wherein the pretreatment unit comprises an airtight decompression tank; an ultrasonic generation device and a magnetic field generation device are arranged in the airtight decompression tank; the peeling unit comprises a centrifugal peeling device and a slicing device; the centrifugal peeling device and the slicingdevice are sequentially mounted; the anti-browning unit comprises an anti-browning induction treatment device, an anti-metal ion induction treatment device and an anti-caramelization browning treatment device; the anti-caking treatment unit comprises a microwave drying device, an anti-caking polarity remover spray device and a freeze drying device; the high-speed nitrogen flow pulverizing unit comprises a nitrogen generating device, a nitrogen tank, a nitrogen pulverizer and a cyclone separator; and the cyclone separator is provided with a multi-stage discharge port.

The invention provides an anti-NGF antibody or an antigen binding fragment thereof, and a preparation method and application thereof. The invention also provides an isolated polynucleotide encoding the anti-NGF antibody or the antigen binding fragment thereof, and a vector comprising the isolated polynucleotide. The invention also provides application of the antibody or the antigen binding fragment thereof in preparation of drugs for treating NGF-mediated diseases or symptoms.

The invention discloses a method for preparing 3,5,5-trimethyl-3-cyclohexene-1-one. The method comprises the following steps: taking 3,5,5-trimethyl-2-cyclohexene-1-one (alpha-IP) as a raw material, taking preazophosphorine as a catalyst, and carrying out an isomerization reaction by adopting a reactive distillation technique, thereby obtaining the 3,5,5-trimethyl-3-cyclohexene-1-one (beta-IP). The purity of the product beta-IP can reach 99.5-99.8wt%, and the reaction selectivity can reach 99.2-99.9%. The process has the advantages of small catalyst usage amount, high selectivity, avoidance of alkaline separation, less high-boiling residues and the like and a high-efficiency synthetic process.

The invention discloses a salt-free pickling method of bamboo shoots. The method comprises the following steps of (1) bamboo shoot collection: collecting square bamboo shoots coming out from the soil and having the length being 20 to 25cm as raw materials; (2) bamboo shoot cutting; cutting the bamboo shoots into strip shapes with the length being 5 to 10cm and the width being 1 to 2cm; (3) pickling: putting the cut bamboo shoots into a pickling jar; pouring lemon enzymes so that the bamboo shoots are immersed by the lemon enzymes; then, adding auxiliary materials; performing sealed fermentation for 3 to 5 days; (4) packaging; (5) sterilization. The bamboo shoots pickled by the invention has more delicious and crispy mouthfeel than that of the bamboo shoots pickled in the prior art; the color and luster is natural; meanwhile, the pure natural lemon fermentation fragrance is realized; various active protein small peptide energy and enzymes are contained in the lemon enzymes, nitrite can be inhibited and killed; the human body digestion system can also be promoted; meanwhile, the fermentation speed is high; the pickling time is short; the pickled bamboo shoots are healthier; the eating is safe.

The invention relates to a monoclonal antibody targeting a nerve growth factor (NGF) and application thereof. The monoclonal antibody contains a heavy chain variable region including CDR-H1 shown in SEQ ID NO:1 or SEQ ID NO:7, CDR-H2 shown in SEQ ID NO:2 or SEQ ID NO:8 and CDR-H3 shown in SEQ ID NO:3 or SEQ ID NO:9, and a light chain variable region including CDR-L1 shown in SEQ ID NO:4 or SEQ IDNO:10, CDR-L2 shown in SEQ ID NO:5 or SEQ ID NO:11 and CDR-L3 shown in SEQ ID NO:6 or SEQ ID NO:12. The monoclonal antibody disclosed by the invention can be applied to research and development of NGFmolecular detection reagents and therapeutic antibodies.

Methods for detecting analytes are provided. A plurality of particles, each of which is coated with a capture agent having an affinity for the analyte is combined with the sample to form a plurality of analyte-particle complexes. The system also includes a transport arrangement for transporting the sample to the sensor surface, and optionally a magnetic field inducing structure constructed and arranged to establish a magnetic field at and adjacent to the sensor surface. The resonant sensor produces a signal corresponding to an amount of analyte-particle complexes that are bound to the sensor surface.

The invention is applicable to the technical field of biology, and provides a coding gene, a vector, an anti-idiotypic nano antibody and a preparation method and application thereof. The amino acid sequence of the anti-idiotypic nano antibody is shown as SEQ ID NO: 2 in a sequence table. The anti-idiotypic nano-antibody is prepared by the following steps: successfully screening the coding gene ofa required anti-idiotypic nano-antibody through a phage display technology, then connecting the coding gene to a pichia pastoris expression vector, and electrically transforming the vector to pichia pastoris competent cells for culturing. The anti-idiotypic nanometer antibody can specifically block the combination of monoclonal antibody 1E7 and PCV2 Cap protein, has the effect of simulating PCV2 Cap key antigenic epitopes, and can be used for developing anti-idiotypic nanometer antibody vaccine, diagnosis reagent, biological reagent and the like for preventing and treating PCV2.

The present invention relates to a method for producing derivatives of wild-type protein allergens with reduced allergenic activity, characterized in by the following steps: providing a wild-type protein allergen with an allergenic activity, splicing said wild-type protein allergen into two parts, said two parts having a reduced allergenic activity or lacking allergenic activity and rejoining said two fragments in inverse orientation; as well as allergen derivatives.

The present invention relates to an anti-rust protective cover for golf club head. It is an iron-cobalt-nickel alloy layer which is formed on the surface of gold club head. Said iron-cobalt-nickel alloy layer composition includes (by wt%) 5%-20% of iron, 5%-25% of cobalt and 60%-90% of nickel. Said anti-rust protective cover can effectively raise the tarnish proofness and relative hardness of said gold club head and increase its service life.

The invention discloses an ACE2 targeting peptide in targeting combination with ACE2 protein and application of the ACE2 targeting peptide. The ACE2 targeting peptide is a polypeptide, and the amino acid sequences of the ACE2 targeting peptide are respectively as follows: FPHWHGNHKHNR, GFKSHFHHNHMR, AHYHRHPPHLNR, LSPHFHHHRGAK, METRPVAPHEFR, LHRPHFHAHNNS, GHQGHWYGMFRA, YPWHHRHHMPVHP, SHKHHWPYHAH and FHGHGSHNKHR; the bioactive substance is formed by forming ACE2 targeting peptide on the surface of a mixture of microorganisms and polymers. The ACE2 protein can be efficiently targeted, the combination of the novel coronavirus spike protein and the ACE2 protein is blocked, and the effect of inhibiting novel coronavirus infection is further achieved.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to an anti-inflammatory active pharmaceutical composition based on radix bupleuri components and a preparation method of the anti-inflammatory active pharmaceutical composition. The components of the composition are from the radix bupleuri, and particularly, the composition consists of the following components in percentages by mass: 10-50% of a radix bupleuri oligosaccharide fragment and 50-90% of radix bupleuri total saponins. According to pharmacological and activity experimental results, the composition can effectively inhibit exudation of white blood cells in the peritoneal fluid of an acute peritonitis mouse model, and shows good anti-inflammatory activity; and the acting mechanism of the composition is closely related to antagonizing leukocyte adhesion mediated by vascular endothelial P-selectin. The results show that the radix bupleuri composition can be used for preparing novel effective medicines for treating acute inflammation, and has wide application prospect.

The invention provides a hot pepper pickling method. In the pickling method, aloe juice, vitamin C tablets and citric acid not only can effectively block synthesis of nitrosamines but also can preventhot peppers from mildewing and reduce rancidity and peculiar smell, therefore, the method provided by the application can effectively reduce the generation of nitrosamines and further can substantially reduce harm to the health of a human body; Chinese wolfberry fruit powder has the effects of nourishing the liver and replenishing vital essence to improve eyesight, so that in the pickling processof the hot peppers, nutrient components in the Chinese wolfberry fruit powder can enter the inner parts of the hot peppers, and nutrient components of the pickled hot peppers can be promoted; and Baijiu can sterilize the hot peppers and pickling material liquid, so that the hot peppers cannot produce rot in the pickling process, and the storage time of the pickled hot peppers can be prolonged.

The invention relates to an application of an anti-PD-L1 / VEGF (platelet death-L1 / vascular endothelial growth factor) bispecific antibody. Specifically, the invention provides an anti-PD-L1 / VEGF bispecific antibody, and the antibody has a function of blocking the combination of PD-L1 and a receptor PD-1 and a function of blocking the combination of VEGF and a receptor thereof. The bispecific antibody can play a better role in killing tumors by activating an immune system and blocking tumor angiogenesis at the same time. Moreover, the invention provides an amino acid sequence of the bispecific antibody, a corresponding expression vector, a host cell capable of expressing the bispecific antibody, and a production method of the bispecific antibody.

The invention relates to the technical field of puer tea processing, in particular to a puer tea processing process for reducing the bitterness degree of summer and fall tea. The processing process comprises the following steps of (1) selecting high-quality withering primary tea with the moisture content being 10 to 11 percent; controlling the pile fermentation temperature to be 50 to 55 DEG C; performing pile fermentation for certain time for use; (2) putting withered primary tea subjected to pile fermentation treatment into material mixing equipment; adding beta-cyclodextrine, tannase and OPanimal albumin powder; uniformly mixing the materials for use; (3) putting the product treated in the step 2 into a round mold paved with a cloth liner; adding 0.1 times of quantity of water; then, performing steam-hot air fixation treatment on the round mold for certain time; (4) pressing tea leaves subjected to steam-hot air fixation treatment into a tea cake; then, drying the tea cake; controlling the moisture to a certain value; obtaining the tea. The processing process disclosed by the invention effectively overcomes the defects of high bitterness degree and liquid color turbidity of theproduct obtained by the existing puer tea processing process.

The invention discloses a fusion protein, a coding nucleic acid, a cell and application. The fusion protein of the present invention comprises a soluble immunoglobulin CD223 as a first part and a soluble programmed death receptor 1 as a second part. The first part is covalently linked to the second part through a linker. The fusion protein disclosed by the invention has a specific Y-shaped structure, so that the functions of the first part and the second part have a synergistic effect, a PD-1 signal channel can be blocked, and an LAG3 signal channel can be blocked, so that inhibition of the PD-1 / LAG3 signal channel on T cells after activation can be effectively relieved, and the anti-tumor function of the T cells is remarkably enhanced.